Remove 2001 Remove Regulations Remove Therapies Remove Trials
article thumbnail

The Moving Regulatory Landscape for Gene Therapy Trials in EU: Part 2

thought leadership

Change in the Submission of the Summary Notification Information Format The Summary Notification Information Format Form As of January 31, 2023, Sponsors are required to submit a Clinical Trial Application (CTA) in the EU through the Clinical Trial Information System (CTIS).

Trials 52
article thumbnail

Can Europe become a major player in cell and gene therapy?

Drug Discovery World

DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies. . Of the total R&D investment made in the US, Europe, China and Japan, only 31% occurs in Europe, which has declined steadily from 41% in 2001. China has meanwhile grown its share from 1% to 8%. .

Therapies 245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Preparing the next generation of drug discovery scientists

Drug Discovery World

This ranges from understanding disease processes and identifying possible drug targets, to organising testing, rolling out clinical trials, negotiating complex regulations and licensing and finally, treating patients. Drug development and clinical trials: How drugs are discovered and developed as medicines.

article thumbnail

Article FDA Thank You The FDA rejected a psychedelic sponsor’s bid for approval. Here are six industry takeaways

Agency IQ

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. Lykos (formerly MAPS PBC) met with the agency in 2016 for the End of Phase 2 meeting.

FDA 40
article thumbnail

Why Sarepta’s most recent failure in DMD was entirely predictable

DrugBaron

Yesterday, Sarpeta (NASDAQ: $SRPT) announced that its gene therapy for Duchenne Muscular Dystrophy failed to improve muscle function in a study of 40 boys, despite achieving impressive expression of micro-dystrophin (at least in the short term). What are the implications of these observations for the future of gene therapy?

DNA 100
article thumbnail

Navigating the Complex Regulatory CRO Landscape for Oncology Trials in the European Union

Conversations in Drug Development Trends

By: Sarah Bly, Regulatory Science and Innovation and Matt Cooper, Executive Director, Therapeutic Strategy Lead, Oncology The European Union (EU) presents a unique set of regulatory challenges and opportunities for clinical trials in oncology. Increased Transparency : Ensures that information on clinical trials is more accessible.

Trials 52
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies 105